Delgocitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan. Among its listed roles, it functions as a anti-inflammatory drug, an antipsoriatic, an antiseborrheic and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a tertiary carboxamide, a nitrile, an azaspiro compound, a pyrrolopyrimidine, a N-acylazetidine and a tertiary amino compound. It is grouped under the following drug class(es): JAK inhibitors. Its therapeutic use is listed as anti-inflammatories and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Corectim and Anzupgo. Its PubChem CID is 50914062.
Delgocitinib
| CAS No | 1263774-59-9 |
|---|---|
| Molecular Formula | C16H18N6O |
| Molecular Weight | 310.35 g/mol |
| Synonyms | 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan. 2 (non-specific protein-tyrosine kinase) inhibitor.
The listed CAS number is 1263774-59-9.
The listed molecular formula is C16H18N6O.
The listed molecular weight is 310.35 g/mol.
3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile.
The source lists Corectim and Anzupgo.